Emi Yamamoto

Part of Carna Biosciences, Inc., ProbeX, Inc. is a Japanese company that develops, manufactures, and distributes molecular imaging probe reagents. The company is based in Tokyo, Japan. ProbeX was acquired by Carna Biosciences, Inc. from Life Science Management, Inc. on October 01, 2013 for $2.82 million.

Hinge Therapeutics, Inc. is an early-stage biopharmaceutical company based in Torrance, CA. The private company focuses on developing small-molecule therapeutics against traditionally undruggable/challenging targets for unmet medical needs. The company's proprietary technology, the Hinge drug discovery platform, has generated several novel inactivators against targets which are traditionally targeted only by large molecules such as antibody and siRNA. The current areas of interest include bleeding disorders, solid tumors, cardiovascular diseases, CNS, rare disease, and anti-aging. Hinge Therapeutics is seeking investors/partners who can help them advance their programs while further establishing their "Hinge drug discovery platform" which can be applied to many other challenging targets. The company was founded by Yoshihiko Futamura, and the CEO is Akiko Futamura.

Institute of Accelerator Analysis Ltd. provides accelerator mass spectrometry analysis services. Its specializes in pharmacokinetic analysis and radiocarbon dating. The firm also offers in-vitro studies in the early stages of drug development as well as drug concentration measurement in biological samples. The company was founded by Takao Mutsui on March 29, 1999 and is headquartered in Kawasaki, Japan.